Company / R&D Expense
Penumbra, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$89.8M
FY2025
5-year range
$51.7M / $94.8M
FY2021-FY2025
Trend
-5.3%
vs FY2024
Sector context
#61 of 110
Health Care
What the data says
At $90M, Penumbra, Inc.'s r&d expense ranks #61 of 110 in the Health Care sector. R&D Expense has fluctuated over the past 10 years, ranging from $18M in FY2017 to $95M in FY2024.
Based on SEC 10-K filings.
$90M in FY2025 with a 5-year CAGR of -0.1%.
Improved from $84M to $90M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -0.1%
- 5-Year CAGR
- -0.1%
- 10-Year CAGR
- -
Sector benchmark
#61 of 110 in Health CareTop 55% of 110This company $89.8M Sector average $298.2M
▼
-69.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -0.1%, indicating a declining trend.
- In FY2025, r&d expense decreased 5.3% year-over-year.
- Ranks #61 out of 110 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 3.11 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $89.8M | -5.3% |
| FY2024 | $94.8M | +12.3% |
| FY2023 | $84.4M | -6.2% |
| FY2022 | $90.0M | +74.1% |
| FY2021 | $51.7M | -42.6% |
| FY2020 | $90.0M | +184.4% |
| FY2019 | $31.7M | +32.6% |
| FY2018 | $23.9M | +32.4% |
| FY2017 | $18.0M | -24.5% |
| FY2016 | $23.9M | +32.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026